Leukemia Therapeutics Treatment Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,000	250 Pages	Future Market Insights	June, 2022	FMARI17844003

Best Price Guarantee
Price	from $5,000
Length	250 Pages
Publisher	Future Market Insights
Published Date	June, 2022
SKU	FMARI17844003

Leukemia Therapeutics Treatment Market

Leukemia is defined as a cancer observed in white blood cell (WBC) in our body. White blood cell helps our body to fight against infection caused by harmful pathogen. Bone marrow is the center for the production of RBC (carry oxygen to all part of body), WBC (fight against infection) and platelets (help in blood clotting). Our bone marrow produces abnormal WBC when we are suffering from leukemia. Moreover abnormal WBCs are not able to perform normal functioning or WBC loses its ability to fight against infection. Etiology for leukemia includes artificial ionizing radiation, benzene and petrochemicals, alkylation chemotherapy agents, genetic predisposition and electromagnetic energy. Genetic predisposition and electromagnetic energy is the most common cause of leukemia observed among people. Signs and symptoms of leukemia includes a new lump or swollen gland in neck and arm, frequent nosebleed, pain in the bone, night sweat and frequent fever. Leukemia can be diagnosed by bone marrow tests, platelet count and WBC (white blood cell) differential count test. Leukemia can be treated by blood transfusion, immunotherapy, bone marrow transplantation, radiation therapy and chemotherapy.

Commercially available drug in the market for the treatment of leukemia includes Gleevec, Bosulif, Sprycel, Iclusig and others. Drugs which are in clinical trials expected to launch in the marketwithin next few (3 to 5)years include Bosutinib, Omapro, ga101/rg7159, Vidaza, Dacogen, Midostaurin, Vosaroxin, Quizartinib, Graspa, Marqibo.

The global market for leukemia treatment can be segmented as follows:

Based on the developmental and progression rate

Chronic leukemia

Acute leukemia

Chronic leukemia is a type of blood cancer caused by uncontrolled growth of the WBC cells in our body. Chronic leukemia is a type of myeloproliferative disease which is characterized by the chromosomal translocation. Patients suffering from chronic leukemia show increased susceptibility to bacterial infections, thrombocytopenia and anemia and may also have enlarged spleen which causes pain on the left side. Incidence rate of chronic leukemia is high in men and is the second most common type of cancer occurring in male adults. Women who are above 50 years in age are expected to suffer from this chronic disease. Treatment for chronic leukemia depends on the phase of the disease that can be chronic, accelerated or the blast phase and the treatment for chronic leukemia includes chemotherapy, stem cell transplants and biologic therapies.

Acute myeloid leukemia develops at a speedy pace and is found in the blood and bone marrow. In the disease process, immature blood cells are present in the bone marrow. Symptoms found in patients due to the disease are flu, loss of weight, body ache, body pain and spots on skin.Treatment for acute leukemia includes chemotherapy, stem cell transplants and biologic therapies.

About 90% of the leukemia cases occur in the middle age and progresses with the aging. Therefore, leukemia therapeutics market is poised to grow with the rise in aging population and increasing incidences of leukemia. Drugs such as Bosulif, Gleevec, Sprycel andIclusigare commercially available for the treatment of leukemia. Gleevec was the first leukemia drug introduced in 2001, since then there has been a revolutionary change in the quality life of patients as compared to the former chemotherapy drugs.Globally the numbers of elderly people, 60 years and above are growing and it is expected that this age group will cross the 2 billion mark in 2050 stated by United Nations Population Division. Hence the leukemia therapeutics market will also grow significantly.However adverse event (cytotoxic) associated with nearly all kinds of leukemia therapeutics treatment might restrict the global market demand of leukemia therapeutics market.

North America dominates the global market for leukemia therapeutics treatment due to high prevalence rate of leukemia (acute, chronic) and extensive technological advancement (diagnosis) in this region. Europe represents the second largest market share due to its large geriatric population base. In addition Asia-Pacific and RoW hold the third and fourth position in the global leukemia therapeutics market respectively due to less prevalence rate of leukemia and lack of proper healthcare facilities in few Asian and African countries.

North America accounted for 62% sales of leukemia drugs in the therapeutics market during 2010 followed by Europe and Asia Pacific. Leukemia therapeutics market will grow significantlyand the total growth will depend on pipeline products and metabolic inhibitors, a tyrosine kinase receptor FLT -3 of Novartis and some other capable molecules, improving the therapeutics market.

Major market playerscontributing the global market share of leukemia therapeutics treatment includes Ambit Biosciences Corporation, AriadPharmaceuticals,Inc., Biogen Idec, Inc., Novartis Pharmaceuticals, Bristol-Myers Squibb, Pfizer and others.

This research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data and statistically-supported and industry-validated market data and projections with a suitable set of assumptions and methodology. It provides analysis and information by categories such as market segments, regions, product types and distribution channels.

The report covers exhaustive analysis on:

Market Segments

Market Dynamics

Historical Actual Market Size, 2012 - 2014

Market Size & Forecast 2015 to 2025

Supply & Demand Value Chain

Current Trends/Issues/Challenges

Competition & Companies involved

Technology

Value Chain

Market Drivers and Restraints

Regional analysis includes

North America

US & Canada

Latin America

Brazil, Argentina & Others

Western Europe

EU5

Nordics

Benelux

Eastern Europe

Asia Pacific

Australia and New Zealand (ANZ)

Greater China

India

ASEAN

Rest of Asia Pacific

Japan

Middle East and Africa

GCC Countries

Other Middle East

North Africa

South Africa

Other Africa

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics of the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

A neutral perspective towards market performance

Must-have information for market players to sustain and enhance their market footprint

1. Executive Summary: 1.1. Global Market Outlook; 1.2. Demand-side Trends; 1.3. Supply-side Trends; 1.4. Technology Roadmap Analysis; 1.5. Analysis and Recommendations
2. Market Overview: 2.1. Market Coverage / Taxonomy; 2.2. Market Definition / Scope / Limitations
3. Market Background: 3.1. Market Dynamics; 3.1.1. Drivers; 3.1.2. Restraints; 3.1.3. Opportunity; 3.1.4. Trends; 3.2. Scenario Forecast; 3.2.1. Demand in Optimistic Scenario; 3.2.2. Demand in Likely Scenario; 3.2.3. Demand in Conservative Scenario; 3.3. Opportunity Map Analysis; 3.4. Investment Feasibility Matrix; 3.5. Value Chain Analysis; 3.5.1. Profit Margin Analysis; 3.5.2. Service Providers; 3.6. PESTLE and Porter’s Analysis; 3.7. Regulatory Landscape; 3.7.1. By Key Regions; 3.7.2. By Key Countries; 3.8. Regional Parent Market Outlook
4. Global Market Analysis 2017-2021 and Forecast, 2022-2032: 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021; 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032; 4.2.1. Y-o-Y Growth Trend Analysis; 4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Therapy Type: 5.1. Introduction / Key Findings; 5.2. Historical Market Size Value (US$ Mn) Analysis By Therapy Type, 2017-2021; 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapy Type, 2022-2032; 5.3.1. Chemo-therapy; 5.3.2. Stem Cell Therapy; 5.3.3. Others; 5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2017-2021; 5.5. Absolute $ Opportunity Analysis By Therapy Type, 2022-2032 Deep-dive segmentation will be available in the sample on request
6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration: 6.1. Introduction / Key Findings; 6.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2017-2021; 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032; 6.3.1. Orally; 6.3.2. Intravenously; 6.3.3. Intrathecally; 6.3.4. Others; 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021; 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032 Deep-dive segmentation will be available in the sample on request
7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Type: 7.1. Introduction / Key Findings; 7.2. Historical Market Size Value (US$ Mn) Analysis By Disease Type, 2017-2021; 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Type, 2022-2032; 7.3.1. AML (Acute Myeloid Leukaemia); 7.3.2. ALL (Acute Lymphoblastic Leukaemia); 7.3.3. CLL (Chronic Lymphocytic Leukaemia); 7.4. Y-o-Y Growth Trend Analysis By Disease Type, 2017-2021; 7.5. Absolute $ Opportunity Analysis By Disease Type, 2022-2032 Deep-dive segmentation will be available in the sample on request
8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By End User: 8.1. Introduction / Key Findings; 8.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021; 8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032; 8.3.1. Hospitals; 8.3.2. Research Institutes; 8.3.3. Others; 8.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021; 8.5. Absolute $ Opportunity Analysis By End User, 2022-2032 Deep-dive segmentation will be available in the sample on request
9. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region: 9.1. Introduction; 9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021; 9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032; 9.3.1. North America; 9.3.2. Latin America; 9.3.3. Europe; 9.3.4. East Asia; 9.3.5. South Asia & Pacific; 9.3.6. MEA; 9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 10.2.1. By Country; 10.2.1.1. U.S.; 10.2.1.2. Canada; 10.2.2. By Therapy Type; 10.2.3. By Route of Administration; 10.2.4. By Disease Type; 10.2.5. By End User; 10.3. Market Attractiveness Analysis; 10.3.1. By Country; 10.3.2. By Therapy Type; 10.3.3. By Route of Administration; 10.3.4. By Disease Type; 10.3.5. By End User; 10.4. Key Takeaways
11. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 11.2.1. By Country; 11.2.1.1. Mexico; 11.2.1.2. Brazil; 11.2.1.3. Rest of Latin America; 11.2.2. By Therapy Type; 11.2.3. By Route of Administration; 11.2.4. By Disease Type; 11.2.5. By End User; 11.3. Market Attractiveness Analysis; 11.3.1. By Country; 11.3.2. By Therapy Type; 11.3.3. By Route of Administration; 11.3.4. By Disease Type; 11.3.5. By End User; 11.4. Key Takeaways
12. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 12.2.1. By Country; 12.2.1.1. Germany; 12.2.1.2. Italy; 12.2.1.3. France; 12.2.1.4. U.K.; 12.2.1.5. Spain; 12.2.1.6. BENELUX; 12.2.1.7. Russia; 12.2.1.8. Rest of Europe; 12.2.2. By Therapy Type; 12.2.3. By Route of Administration; 12.2.4. By Disease Type; 12.2.5. By End User; 12.3. Market Attractiveness Analysis; 12.3.1. By Country; 12.3.2. By Therapy Type; 12.3.3. By Route of Administration; 12.3.4. By Disease Type; 12.3.5. By End User; 12.4. Key Takeaways
13. East Asia Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 13.2.1. By Country; 13.2.1.1. China; 13.2.1.2. Japan; 13.2.1.3. South Korea; 13.2.2. By Therapy Type; 13.2.3. By Route of Administration; 13.2.4. By Disease Type; 13.2.5. By End User; 13.3. Market Attractiveness Analysis; 13.3.1. By Country; 13.3.2. By Therapy Type; 13.3.3. By Route of Administration; 13.3.4. By Disease Type; 13.3.5. By End User; 13.4. Key Takeaways
14. South Asia & Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 14.2.1. By Country; 14.2.1.1. India; 14.2.1.2. ASEAN; 14.2.1.3. Australia and New Zealand; 14.2.1.4. Rest of South Asia & Pacific; 14.2.2. By Therapy Type; 14.2.3. By Route of Administration; 14.2.4. By Disease Type; 14.2.5. By End User; 14.3. Market Attractiveness Analysis; 14.3.1. By Country; 14.3.2. By Therapy Type; 14.3.3. By Route of Administration; 14.3.4. By Disease Type; 14.3.5. By End User; 14.4. Key Takeaways
15. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 15.2.1. By Country; 15.2.1.1. GCC Countries; 15.2.1.2. Turkey; 15.2.1.3. South Africa; 15.2.1.4. Rest of MEA; 15.2.2. By Therapy Type; 15.2.3. By Route of Administration; 15.2.4. By Disease Type; 15.2.5. By End User; 15.3. Market Attractiveness Analysis; 15.3.1. By Country; 15.3.2. By Therapy Type; 15.3.3. By Route of Administration; 15.3.4. By Disease Type; 15.3.5. By End User; 15.4. Key Takeaways
16. Key Countries Market Analysis: 16.1. U.S.; 16.1.1. Pricing Analysis; 16.1.2. Market Share Analysis, 2021; 16.1.2.1. By Therapy Type; 16.1.2.2. By Route of Administration; 16.1.2.3. By Disease Type; 16.1.2.4. By End User; 16.2. Canada; 16.2.1. Pricing Analysis; 16.2.2. Market Share Analysis, 2021; 16.2.2.1. By Therapy Type; 16.2.2.2. By Route of Administration; 16.2.2.3. By Disease Type; 16.2.2.4. By End User; 16.3. Mexico; 16.3.1. Pricing Analysis; 16.3.2. Market Share Analysis, 2021; 16.3.2.1. By Therapy Type; 16.3.2.2. By Route of Administration; 16.3.2.3. By Disease Type; 16.3.2.4. By End User; 16.4. Brazil; 16.4.1. Pricing Analysis; 16.4.2. Market Share Analysis, 2021; 16.4.2.1. By Therapy Type; 16.4.2.2. By Route of Administration; 16.4.2.3. By Disease Type; 16.4.2.4. By End User; 16.5. Germany; 16.5.1. Pricing Analysis; 16.5.2. Market Share Analysis, 2021; 16.5.2.1. By Therapy Type; 16.5.2.2. By Route of Administration; 16.5.2.3. By Disease Type; 16.5.2.4. By End User; 16.6. Italy; 16.6.1. Pricing Analysis; 16.6.2. Market Share Analysis, 2021; 16.6.2.1. By Therapy Type; 16.6.2.2. By Route of Administration; 16.6.2.3. By Disease Type; 16.6.2.4. By End User; 16.7. France; 16.7.1. Pricing Analysis; 16.7.2. Market Share Analysis, 2021; 16.7.2.1. By Therapy Type; 16.7.2.2. By Route of Administration; 16.7.2.3. By Disease Type; 16.7.2.4. By End User; 16.8. U.K.; 16.8.1. Pricing Analysis; 16.8.2. Market Share Analysis, 2021; 16.8.2.1. By Therapy Type; 16.8.2.2. By Route of Administration; 16.8.2.3. By Disease Type; 16.8.2.4. By End User; 16.9. Spain; 16.9.1. Pricing Analysis; 16.9.2. Market Share Analysis, 2021; 16.9.2.1. By Therapy Type; 16.9.2.2. By Route of Administration; 16.9.2.3. By Disease Type; 16.9.2.4. By End User; 16.10. BENELUX; 16.10.1. Pricing Analysis; 16.10.2. Market Share Analysis, 2021; 16.10.2.1. By Therapy Type; 16.10.2.2. By Route of Administration; 16.10.2.3. By Disease Type; 16.10.2.4. By End User; 16.11. Russia; 16.11.1. Pricing Analysis; 16.11.2. Market Share Analysis, 2021; 16.11.2.1. By Therapy Type; 16.11.2.2. By Route of Administration; 16.11.2.3. By Disease Type; 16.11.2.4. By End User; 16.12. China; 16.12.1. Pricing Analysis; 16.12.2. Market Share Analysis, 2021; 16.12.2.1. By Therapy Type; 16.12.2.2. By Route of Administration; 16.12.2.3. By Disease Type; 16.12.2.4. By End User; 16.13. Japan; 16.13.1. Pricing Analysis; 16.13.2. Market Share Analysis, 2021; 16.13.2.1. By Therapy Type; 16.13.2.2. By Route of Administration; 16.13.2.3. By Disease Type; 16.13.2.4. By End User; 16.14. South Korea; 16.14.1. Pricing Analysis; 16.14.2. Market Share Analysis, 2021; 16.14.2.1. By Therapy Type; 16.14.2.2. By Route of Administration; 16.14.2.3. By Disease Type; 16.14.2.4. By End User; 16.15. India; 16.15.1. Pricing Analysis; 16.15.2. Market Share Analysis, 2021; 16.15.2.1. By Therapy Type; 16.15.2.2. By Route of Administration; 16.15.2.3. By Disease Type; 16.15.2.4. By End User; 16.16. ASEAN; 16.16.1. Pricing Analysis; 16.16.2. Market Share Analysis, 2021; 16.16.2.1. By Therapy Type; 16.16.2.2. By Route of Administration; 16.16.2.3. By Disease Type; 16.16.2.4. By End User; 16.17. Australia and New Zealand; 16.17.1. Pricing Analysis; 16.17.2. Market Share Analysis, 2021; 16.17.2.1. By Therapy Type; 16.17.2.2. By Route of Administration; 16.17.2.3. By Disease Type; 16.17.2.4. By End User; 16.18. GCC Countries; 16.18.1. Pricing Analysis; 16.18.2. Market Share Analysis, 2021; 16.18.2.1. By Therapy Type; 16.18.2.2. By Route of Administration; 16.18.2.3. By Disease Type; 16.18.2.4. By End User; 16.19. Turkey; 16.19.1. Pricing Analysis; 16.19.2. Market Share Analysis, 2021; 16.19.2.1. By Therapy Type; 16.19.2.2. By Route of Administration; 16.19.2.3. By Disease Type; 16.19.2.4. By End User; 16.20. South Africa; 16.20.1. Pricing Analysis; 16.20.2. Market Share Analysis, 2021; 16.20.2.1. By Therapy Type; 16.20.2.2. By Route of Administration; 16.20.2.3. By Disease Type; 16.20.2.4. By End User
17. Market Structure Analysis: 17.1. Competition Dashboard; 17.2. Competition Benchmarking; 17.3. Market Share Analysis of Top Players; 17.3.1. By Regional; 17.3.2. By Therapy Type; 17.3.3. By Route of Administration; 17.3.4. By Disease Type; 17.3.5. By End User
18. Competition Analysis: 18.1. Competition Deep Dive; 18.1.1. Novartis International AG; 18.1.1.1. Overview; 18.1.1.2. Product Portfolio; 18.1.1.3. Profitability by Market Segments; 18.1.1.4. Sales Footprint; 18.1.1.5. Strategy Overview; 18.1.1.5.1. Marketing Strategy; 18.1.1.5.2. Product Strategy; 18.1.1.5.3. Channel Strategy; 18.1.2. GlaxoSmithKline Pharmaceuticals Limited; 18.1.2.1. Overview; 18.1.2.2. Product Portfolio; 18.1.2.3. Profitability by Market Segments; 18.1.2.4. Sales Footprint; 18.1.2.5. Strategy Overview; 18.1.2.5.1. Marketing Strategy; 18.1.2.5.2. Product Strategy; 18.1.2.5.3. Channel Strategy; 18.1.3. Roche; 18.1.3.1. Overview; 18.1.3.2. Product Portfolio; 18.1.3.3. Profitability by Market Segments; 18.1.3.4. Sales Footprint; 18.1.3.5. Strategy Overview; 18.1.3.5.1. Marketing Strategy; 18.1.3.5.2. Product Strategy; 18.1.3.5.3. Channel Strategy; 18.1.4. Bristol-Myers Squibb; 18.1.4.1. Overview; 18.1.4.2. Product Portfolio; 18.1.4.3. Profitability by Market Segments; 18.1.4.4. Sales Footprint; 18.1.4.5. Strategy Overview; 18.1.4.5.1. Marketing Strategy; 18.1.4.5.2. Product Strategy; 18.1.4.5.3. Channel Strategy; 18.1.5. Genmab A/S; 18.1.5.1. Overview; 18.1.5.2. Product Portfolio; 18.1.5.3. Profitability by Market Segments; 18.1.5.4. Sales Footprint; 18.1.5.5. Strategy Overview; 18.1.5.5.1. Marketing Strategy; 18.1.5.5.2. Product Strategy; 18.1.5.5.3. Channel Strategy; 18.1.6. Celgene Corporation; 18.1.6.1. Overview; 18.1.6.2. Product Portfolio; 18.1.6.3. Profitability by Market Segments; 18.1.6.4. Sales Footprint; 18.1.6.5. Strategy Overview; 18.1.6.5.1. Marketing Strategy; 18.1.6.5.2. Product Strategy; 18.1.6.5.3. Channel Strategy; 18.1.7. Biogen; 18.1.7.1. Overview; 18.1.7.2. Product Portfolio; 18.1.7.3. Profitability by Market Segments; 18.1.7.4. Sales Footprint; 18.1.7.5. Strategy Overview; 18.1.7.5.1. Marketing Strategy; 18.1.7.5.2. Product Strategy; 18.1.7.5.3. Channel Strategy; 18.1.8. Pfizer; 18.1.8.1. Overview; 18.1.8.2. Product Portfolio; 18.1.8.3. Profitability by Market Segments; 18.1.8.4. Sales Footprint; 18.1.8.5. Strategy Overview; 18.1.8.5.1. Marketing Strategy; 18.1.8.5.2. Product Strategy; 18.1.8.5.3. Channel Strategy
19. Assumptions & Acronyms Used
20. Research Methodology